Physician profile
Christopher O Morgan
NPI 1255397006
$1,162.11
in general payments reported to CMS, 2019-2025
24 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $44.93 · 2021: $217 · 2022: $157 · 2023: $207 · 2024: $133 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $219.21 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $116.74 | 2021-2025 | Ozempic, Rybelsus, Saxenda |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.68 | 2019-2021 | |
| Amgen INC. | $89.34 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $89.29 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $88.86 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $71.94 | 2019-2025 | Farxiga |
| Abbvie INC. | $49.88 | 2023-2025 | |
| Allergan, INC. | $39.11 | 2019-2020 | |
| Merz North America, INC. | $34.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.73 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.19 | 2021-2022 | |
| Corium, LLC | $23.63 | 2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $21.84 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.19 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $19.14 | 2022 | |
| Dexcom, INC. | $18.21 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $17.19 | 2021 | |
| Shire North American Group INC | $16.37 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.79 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.27 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.82 | 2022 | |
| Boston Scientific Corporation | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.